<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04986410</url>
  </required_header>
  <id_info>
    <org_study_id>2016YFC1300302</org_study_id>
    <nct_id>NCT04986410</nct_id>
  </id_info>
  <brief_title>Quantitative Analysis of Functional CT Imaging of Coronary Atherosclerosis</brief_title>
  <official_title>Quantitative Analysis of Functional Computed Tomography (CT) Imaging of Coronary Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective observational study is to evaluate the diagnostic and&#xD;
      prognostic performance of a &quot;one-stop&quot; comprehensive coronary artery anatomy and function&#xD;
      assessment for CAD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary CT angiography (CCTA) has become a reliable diagnostic technique to evaluate&#xD;
      coronary artery disease (CAD) with high sensitivity and a negative predictive value. However,&#xD;
      CCTA provides only anatomic information and tends to overestimate stenosis severity and is&#xD;
      limited in its ability to diagnose myocardial ischemia. Undertaking additional CT myocardial&#xD;
      perfusion imaging(CT-MPI) and CT-FFR improves specificity and positive predictive value,&#xD;
      reducing unnecessary invasive coronary angiography. The purpose of this prospective&#xD;
      observational study is to evaluate the diagnostic and prognostic performance of a &quot;one-stop&quot;&#xD;
      comprehensive coronary artery anatomy and function assessment for CAD. SPECT myocardial&#xD;
      perfusion imaging (SPECT-MPI)and invasively measured fractional flow reserve (FFR) will serve&#xD;
      as the reference standard.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiovascular Events</measure>
    <time_frame>5 years</time_frame>
    <description>including cardiac death, all-cause death, acute coronary syndrome, readmission for acute coronary syndrome or heart failure, and Revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance of CT-MPI</measure>
    <time_frame>From admission to discharge, up to 1 week</time_frame>
    <description>Diagnostic accuracy, Sensitivity, specificity, negative predictive value(NPV) and positive predictive value(PPV) of CT-perfusion imaging (quantitative and qualitative analysis) to determine the presence/absence of significant coronary artery disease at the subject level when compared with invasive FFR and SPECT-MPI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance of CT-FFR</measure>
    <time_frame>From admission to discharge, up to 1 week</time_frame>
    <description>Diagnostic accuracy, Sensitivity, specificity, negative predictive value(NPV) and positive predictive value(PPV) of CT-FFR to determine the presence/absence of significant coronary artery disease at the subject level when compared with invasive FFR and SPECT-MPI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance of CT-MPI</measure>
    <time_frame>From admission to discharge, up to 1 week</time_frame>
    <description>Diagnostic accuracy, Sensitivity, specificity, negative predictive value(NPV) and positive predictive value(PPV) of CT-perfusion imaging (quantitative and qualitative analysis) to determine the presence/absence of significant coronary artery disease in per-vessel level when compared with invasive FFR and SPECT-MPI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance of CT-FFR</measure>
    <time_frame>From admission to discharge, up to 1 week</time_frame>
    <description>Diagnostic accuracy, Sensitivity, specificity, negative predictive value(NPV) and positive predictive value(PPV) of CT-FFR to determine the presence/absence of significant coronary artery disease in per-vessel level when compared with invasive FFR and SPECT-MPI.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">640</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Myocardial Perfusion examination</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CCTA, CT-MPI, CT-FFR, SPECT-MPI</intervention_name>
    <description>Subjects undergo CCTA, CT-MPI, CT-FFR or SPECT-MPI</description>
    <arm_group_label>Myocardial Perfusion examination</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with known or suspected CAD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Understand the purpose of the trial, voluntarily participate in this study, and have&#xD;
             signed an informed consent form.&#xD;
&#xD;
          3. Patients with known or suspected CAD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with acute coronary syndrome.&#xD;
&#xD;
          2. Severe cardiac dysfunction (LVEF ≤ 0.3).&#xD;
&#xD;
          3. Cardiomyopathy with non-coronary causes such as hypertrophic cardiomyopathy, dilated&#xD;
             cardiomyopathy, alcoholic cardiomyopathy, and myocardial amyloidosis.&#xD;
&#xD;
          4. Severe cardiac valve disease with more than moderate valvular regurgitation and/or&#xD;
             valvular stenosis.&#xD;
&#xD;
          5. Severe hepatic and renal dysfunction (ALT ≥ 3 Upper Limit of Normal, Cr&gt; 134μ/mol/L&#xD;
             (2mg/dl) or estimated Glomerular Filtration Rate&lt;45ml/min/1.73m2).&#xD;
&#xD;
          6. Severe arrhythmias (persistent atrial fibrillation, second-degree or third-degree&#xD;
             atrioventricular block, etc.)&#xD;
&#xD;
          7. Malignancy or other pathophysiological conditions with an expected survival of less&#xD;
             than 1 year&#xD;
&#xD;
          8. Allergic to the drug components involved in this study and those who are intolerant to&#xD;
             loading tests&#xD;
&#xD;
          9. Pregnant or lactating women.&#xD;
&#xD;
         10. Mental disorders.&#xD;
&#xD;
         11. Failure to sign the informed consent form.&#xD;
&#xD;
         12. Other conditions that are incompatible with the clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mei Zhang</last_name>
    <role>Study Chair</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mei Zhang</last_name>
    <role>Study Director</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 11, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CT myocardial perfusion imaging</keyword>
  <keyword>SPECT myocardial perfusion imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

